Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

A E Gliddon; C J Doré; C M Black; Neil J McHugh; R Moots; C P Denton; A Herrick; T Barnes; J Camilleri; K Chakravarty; P Emery; B Griffiths; N D Hopkinson; P Hickling; P Lanyon; C Laversuch; T Lawson; R Mallya; M Nisar; C Rhys-Dillon; T Sheeran; P J Maddison

doi:10.1002/art.22965

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

A E Gliddon, C J Doré, C M Black, Neil J McHugh, R Moots, C P Denton, A Herrick, T Barnes, J Camilleri, K Chakravarty, P Emery, B Griffiths, N D Hopkinson, P Hickling, P Lanyon, C Laversuch, T Lawson, R Mallya, M Nisar, C Rhys-DillonT Sheeran, P J Maddison

Research output: Contribution to journal › Article › peer-review

109 Citations (SciVal)

Abstract

Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.

Original language	English
Pages (from-to)	3837-46
Number of pages	10
Journal	Arthritis & Rheumatism
Volume	56
Issue number	11
DOIs	https://doi.org/10.1002/art.22965
Publication status	Published - 2007

Access to Document

10.1002/art.22965

Fingerprint

Dive into the research topics of 'Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril'. Together they form a unique fingerprint.

Cite this

Gliddon, A. E., Doré, C. J., Black, C. M., McHugh, N. J., Moots, R., Denton, C. P., Herrick, A., Barnes, T., Camilleri, J., Chakravarty, K., Emery, P., Griffiths, B., Hopkinson, N. D., Hickling, P., Lanyon, P., Laversuch, C., Lawson, T., Mallya, R., Nisar, M., ... Maddison, P. J. (2007). Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis & Rheumatism, 56(11), 3837-46. https://doi.org/10.1002/art.22965

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. / Gliddon, A E; Doré, C J; Black, C M et al.
In: Arthritis & Rheumatism, Vol. 56, No. 11, 2007, p. 3837-46.

Research output: Contribution to journal › Article › peer-review

Gliddon, AE, Doré, CJ, Black, CM, McHugh, NJ, Moots, R, Denton, CP, Herrick, A, Barnes, T, Camilleri, J, Chakravarty, K, Emery, P, Griffiths, B, Hopkinson, ND, Hickling, P, Lanyon, P, Laversuch, C, Lawson, T, Mallya, R, Nisar, M, Rhys-Dillon, C, Sheeran, T & Maddison, PJ 2007, 'Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril', Arthritis & Rheumatism, vol. 56, no. 11, pp. 3837-46. https://doi.org/10.1002/art.22965

@article{32821c52e3094b91b303d2f22ad0b728,

title = "Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril",

abstract = "Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.",

author = "Gliddon, {A E} and Dor{\'e}, {C J} and Black, {C M} and McHugh, {Neil J} and R Moots and Denton, {C P} and A Herrick and T Barnes and J Camilleri and K Chakravarty and P Emery and B Griffiths and Hopkinson, {N D} and P Hickling and P Lanyon and C Laversuch and T Lawson and R Mallya and M Nisar and C Rhys-Dillon and T Sheeran and Maddison, {P J}",

year = "2007",

doi = "10.1002/art.22965",

language = "English",

volume = "56",

pages = "3837--46",

journal = "Arthritis & Rheumatism",

issn = "0004-3591",

publisher = "John Wiley & Sons",

number = "11",

}

TY - JOUR

T1 - Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

AU - Gliddon, A E

AU - Doré, C J

AU - Black, C M

AU - McHugh, Neil J

AU - Moots, R

AU - Denton, C P

AU - Herrick, A

AU - Barnes, T

AU - Camilleri, J

AU - Chakravarty, K

AU - Emery, P

AU - Griffiths, B

AU - Hopkinson, N D

AU - Hickling, P

AU - Lanyon, P

AU - Laversuch, C

AU - Lawson, T

AU - Mallya, R

AU - Nisar, M

AU - Rhys-Dillon, C

AU - Sheeran, T

AU - Maddison, P J

PY - 2007

Y1 - 2007

N2 - Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.

AB - Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.

UR - http://dx.doi.org/10.1002/art.22965

U2 - 10.1002/art.22965

DO - 10.1002/art.22965

M3 - Article

SN - 0004-3591

VL - 56

SP - 3837

EP - 3846

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - 11

ER -

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

Abstract

Access to Document

Other files and links

Fingerprint

Cite this